Kiniksa Pharmaceuticals International, plc (KNSA)

KNSA Revenue

Kiniksa Pharmaceuticals International, had revenue of $285.97M in the quarter ending September 30, 2026, with 58.12% growth. This brings the company's total for the last twelve months to $945.96M, up 58.19% year-over-year. In the year 2025, Kiniksa Pharmaceuticals International, had annual revenue of $677.56M with 60.09% growth. That makes Kiniksa Pharmaceuticals International, the 7,910th largest company in the world by revenue and 1,834th in the United States.

• Revenue (ttm): $945.96M
• Revenue Growth: +58.19%
• P/S Ratio: 7.90
• Revenue / Employee: $2,584,598
• Employees: 366
• Market Cap: 7.46B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Product Revenue, Net 417.03M 98.5%
• License and Collaboration 6.21M 1.5%

By Geography

Chart

• United States 421.43M 99.6%
• United Kingdom 930.00K 0.2%
• Rest of World 875.00K 0.2%

Fiscal year ended Dec 31, 2024 See the full KNSA breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	677.56M	254.33M	60.09%
Dec 31, 2024	423.24M	152.98M	56.60%
Dec 31, 2023	270.26M	50.08M	22.74%
Dec 31, 2022	220.18M	181.64M	471.24%
Dec 31, 2021	38.54M	-	-

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment and geography data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Nov 7, 2026

Data Sources Report a data error